MFAT (microfragmented adipose tissue, from your fat) and BMA (bone marrow aspirate, from your pelvis) are the two autologous stem cell sources. They are alternatives, never combined, and neither is universally better. The right one is a physician decision made for your specific joint, from imaging, your age, body composition, the stage of arthritis, and prior procedures, not whichever source a clinic happens to stock. At Dynamic Athlete, Dr. Aneesh Garg, DO, CAQ selects the source, then co-delivers it with High-Dose PRP and Fibrin-Rich Plasma under live ultrasound, as the Dynamic Stem Cell+ protocol.
If you searched MFAT vs BMA, you want to know which one is right for you. The honest answer is that the choice is the medicine. So judge a clinic on whether a physician makes that choice from your imaging, or sells you the one source it owns.
MFAT and BMA, compared
Two sources of your own regenerative tissue, two harvest sites, one decision.
| MFAT | BMA | |
|---|---|---|
| What it is | Microfragmented adipose tissue | Bone marrow aspirate |
| Harvest site | Your own fat (mini-liposuction) | Your own iliac crest (pelvis) |
| Cell profile | Dense structural scaffold from fat | Marrow-derived cell population |
| Often chosen for | A more degenerated joint; fat tolerates the environment well | Cases where a marrow-derived population is the better match |
| Co-delivered with | High-Dose PRP and Fibrin-Rich Plasma | High-Dose PRP and Fibrin-Rich Plasma |
What is the same, and what differs
Both are autologous, same-day, minimally manipulated procedures: your own tissue, not a donor vial or a drug. Whichever is selected, it is co-delivered with High-Dose PRP and Fibrin-Rich Plasma and placed under live ultrasound. What differs is the harvest and the cell profile. MFAT comes from a small volume of fat and gives a dense structural scaffold that tolerates a degenerated joint well, so it is frequently chosen for a more arthritic joint. BMA is drawn from the pelvis and supplies a marrow-derived population. Neither is a default.
Why the choice is the medicine?
The variable that decides your result is not which source is fashionable. It is whether a physician matched the source to your joint, and whether it was paired and placed correctly.
The source is selected from your imaging, not from a menu
Dr. Garg weighs the stage of arthritis on your imaging, the joint, your age and body composition, prior procedures, and your goals, then names MFAT or BMA. The evidence supports both for knee osteoarthritis: a 2022 randomized trial in The American Journal of Sports Medicine found bone marrow aspirate concentrate and PRP produced equivalent two-year outcomes. With both supported, the decision belongs to the joint in front of you, not to whichever source a clinic stocks.
Whichever source, it is never injected alone!
Neither MFAT nor BMA goes in bare. The selected source is always co-delivered with High-Dose PRP, platelets concentrated 12 to 20 times baseline (around 10 billion), versus the 2 to 3 times most clinics produce, plus Fibrin-Rich Plasma. The platelets and fibrin are the signaling and scaffolding environment around the cells, and the fibrin helps keep the material at the target. Source plus High-Dose PRP is the pairing that matters, not MFAT plus BMA.
The physician who chooses the source also performs it
Stem cell therapy is image-guided medicine, not a commodity injection. The harvest, the preparation, and the placement each carry judgment. Every Dynamic Stem Cell+ procedure is performed by Dr. Aneesh Garg, DO, CAQ, from source selection through live ultrasound delivery, not a technician. He is regenerative-medicine teaching faculty at RMTI and Rocky Vista University, the physician who teaches this work to other physicians.
Print this before you choose a source!
Three questions separate a physician-selected source from a single product sold under the stem cell label. Ask all three. Most clinics will fail at least one.
Ask it before you book.
- Do you offer both MFAT and BMA, and does a physician select the source for my joint? A clinic that stocks one source recommends that source to everyone.
- Is this my own tissue, MFAT or BMA, rather than a donor vial? An amniotic or umbilical cord product is a different category that may not contain living cells.
- Who performs it, and is it placed under live ultrasound? “The physician, under live ultrasound” and “High-Dose PRP at 12 to 20 times baseline” are the answers you want.
Frequently asked questions
What is the difference between MFAT and BMA?
MFAT and BMA are two sources of your own regenerative tissue, and they are alternatives, not a combination. MFAT (microfragmented adipose tissue) is harvested from your own fat through a mini-liposuction step, then mechanically processed into small fragments without enzymes; fat is a dense source of regenerative and structural cells and tolerates a degenerated joint environment well. BMA (bone marrow aspirate) is drawn from your own iliac crest, the pelvis, and supplies a marrow-derived cell population. Both are autologous, same-day, minimally manipulated procedures, not donor vials and not manufactured drugs. The difference patients should care about is not which acronym sounds stronger; it is which source matches your joint. At Dynamic Athlete, Dr. Aneesh Garg, DO, CAQ selects the source for each case rather than defaulting to whichever one the clinic happens to stock.
Is MFAT or BMA better for stem cell therapy?
Neither MFAT nor BMA is universally better; the right source depends on the joint, the pathology, and the patient, which is exactly why source selection should be a physician decision rather than whatever a clinic stocks. Microfragmented adipose tissue (MFAT) provides a dense structural scaffold from a small volume of fat and tolerates a degenerated joint environment well. Bone marrow aspirate (BMA) provides a marrow-derived cell population drawn from the pelvis. The published evidence base supports both for knee osteoarthritis, and a 2022 randomized trial in The American Journal of Sports Medicine found bone marrow aspirate concentrate and platelet-rich plasma produced equivalent two-year outcomes. So the better source is the one chosen for your specific case from imaging and history, then co-delivered with High-Dose PRP, never a single product sold to everyone.
How does a physician decide between MFAT and BMA?
The decision is made for your specific joint, from imaging and history, not from a menu. Dr. Aneesh Garg, DO, CAQ weighs the stage of arthritis on your imaging, your age and body composition, the joint being treated, prior procedures, and your goals. For a more degenerated joint, fat often tolerates the environment well, so MFAT is frequently the source chosen; for other joints and patients, a marrow-derived population from BMA may be the better match. Body composition matters too: there must be enough harvestable fat for MFAT, while BMA depends on a healthy marrow draw. This is why the source should be named after the evaluation, not before. The goal is to match the source to the actual condition of the joint, not to sell a single procedure to everyone who walks in.
Can MFAT and BMA be combined in one procedure?
At Dynamic Athlete, MFAT and BMA are treated as alternatives, not combined into a single injection. They are two routes to the same goal, your own regenerative tissue placed in the joint, and the medicine is choosing the right route for your case rather than stacking both. What is always combined is the supporting biologic environment: whichever source is selected, it is co-delivered with High-Dose PRP, platelets concentrated 12 to 20 times baseline, around 10 billion, plus Exosome-Containing Fibrin-Rich Plasma. The platelets and fibrin act as the signaling and scaffolding environment around the cells, and the fibrin matrix helps keep the material where it is placed. So the pairing that matters is source plus High-Dose PRP, under live ultrasound, not MFAT plus BMA.
Why is the stem cell source always paired with High-Dose PRP?
At Dynamic Athlete, neither MFAT nor BMA is injected alone. The selected source is always co-delivered with High-Dose PRP, where platelets are concentrated 12 to 20 times baseline, around 10 billion platelets, versus the 2 to 3 times most clinics produce, plus Exosome-Containing Fibrin-Rich Plasma. The platelets and fibrin form the signaling and scaffolding environment around the cells, and the fibrin matrix helps keep the material at the target rather than dispersing. This is why dose and delivery matter as much as the cellular source itself. The combination is the Dynamic Stem Cell+ protocol, built so the regenerative tissue arrives in a supportive biologic environment and at the precise target under live ultrasound. A bare stem cell injection without a strong platelet dose or imaging guidance is a thinner, less coherent version of the same idea.
Does the source change how the procedure is done or recovery?
Both MFAT and BMA are same-day, in-office procedures with no general anesthesia, and the harvest is the main difference patients notice. MFAT involves a small mini-liposuction step to collect fat, usually from the abdomen or flank, which is then processed into microfragments. BMA involves a marrow aspiration from the iliac crest of the pelvis. After harvest, both are co-delivered with High-Dose PRP and Fibrin-Rich Plasma into the target joint under live ultrasound. Most patients walk out the same day and resume daily activity within days, with a graded return to loading. The recovery arc is similar across sources; the harvest site differs. Your evaluation covers which harvest applies to you and what to expect, so there are no surprises on the day of the procedure.
Do MFAT and BMA actually work for knee arthritis?
The orthobiologic evidence for both sources in knee osteoarthritis is encouraging but still maturing, and honesty about that is part of the medicine. Published prospective studies and systematic reviews of microfragmented adipose tissue, and of bone marrow aspirate concentrate, report improvements in pain and function for many patients with knee osteoarthritis, though trials vary in technique, dose, and how outcomes are measured. There is no guaranteed result, and any clinic that promises one should be a warning sign. At Dynamic Athlete, over 90% of our patients self-report a 75% or greater improvement, all without surgery, with the Dynamic Stem Cell+ protocol. That figure is self-reported, not a guarantee, and your candidacy is assessed individually. What a clinic controls is source selection, the co-delivered platelet dose, and ultrasound-guided placement by the physician.
What should I ask a Boulder clinic before choosing a stem cell source?
Ask three direct questions before booking stem cell therapy at any Boulder clinic, and most will fail at least one. First: do you offer both MFAT and BMA, and does a physician select the source for my specific joint, or do you only stock one option? A clinic that owns one source will recommend that source to everyone. Second: is this my own tissue, MFAT or BMA, rather than an amniotic or umbilical cord vial, which is a different category that may not contain living cells? Third: who performs the procedure and how is it placed, by the physician under live ultrasound, or by feel? At Dynamic Athlete, both sources are available, the source is selected by Dr. Aneesh Garg, DO, CAQ from your imaging, and the entire Dynamic Stem Cell+ procedure is performed by him under live ultrasound, never a technician.
See whether MFAT or BMA is the right source for your joint
Imaging-based staging, then Dynamic Stem Cell+ MFAT or BMA, physician-selected and co-delivered with High-Dose PRP under live ultrasound, by Dr. Garg.